Celgene (CELG) Release: Post-Hoc Analysis Of Overall Survival In Phase III MPACT Study Of Patients With Advanced Pancreatic Cancer Presented At American Society of Clinical Oncology 2014
6/2/2014 9:23:40 AM
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Help employers find you! Check out all the jobs and post your resume.
comments powered by